江中药业更名 高层换血+治理结构变动能否扭转困境

Group 1 - The company has completed the registration process for a name change to "China Resources Jiangzhong Pharmaceutical Co., Ltd." and will change its stock abbreviation to "China Resources Jiangzhong" while retaining its stock code [1][2] - This name change is seen as a significant step in the brand integration of the Chinese medicine sector under the China Resources Group, enhancing brand recognition and market influence [1][2] - Alongside the name change, there have been significant management and governance changes, including the resignation of the general manager and financial director, and the restructuring of the board [1] Group 2 - For the first three quarters of 2025, the company reported revenue of 2.933 billion yuan, a year-on-year decline of 6.28%, with a more pronounced drop in the third quarter [2] - The core over-the-counter drug business saw a revenue decrease to 2.086 billion yuan in the third quarter, down 10.65% year-on-year, raising concerns about the sustainability of its growth model [2] - The market is closely watching how the newly named "China Resources Jiangzhong" will consolidate its existing advantages while seeking new growth paths [2]